{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T10:41:20Z","timestamp":1795084880800,"version":"4.10.2"},"reference-count":30,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2017,2,21]],"date-time":"2017-02-21T00:00:00Z","timestamp":1487635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Triple Negative Breast Cancers (TNBC) subtype is an aggressive disease with poor clinical outcome. The only treatment available is surgery followed by chemotherapy or radiotherapy. Programmed death-ligand 1 (PD-L1) is a trans-membrane protein expressed on a wide variety of cells including immune cells, epithelial and vascular endothelial cells. Recently, PD-1\/PD-L1 pathway signaling was described as an adaptive immune resistance mechanism enacted by the tumor cells to evade the immune response. Its presence on tumor cell membranes, acquired for this reason, through time, is an important prognostic value. However, data available in the literature about PD-L1 immunohistochemical expression in breast cancer are often discordant and not uniform, probably for the use of different antibodies clones and the high molecular heterogeneity of the different tumor types. The absence of target therapies, in particular for TNBC, has shifted the clinical attention mainly on the role of PD-L1 in this subtype of breast cancer. In this study, we evaluated tumor and TIL (tumor infiltrating lymphocytes) PDL-1 expression in a series of TNBC, included in Tissue Micro Arrays (TMAs), to define its real prognostic value, optimizing immunohistochemistry method with an \u201capproved for diagnostic assay\u201d antibody. PD-L1 expression directly correlated with proliferation index (Ki-67), glycemia, the presence of diabetes and indirectly with menopausal status, presence of lymph node metastasis and relapse. The analysis of Kaplan\u2013Meier showed that an increased PD-L1 expression was strongly associated with better disease-free survival (DFS) but not correlated with overall survival (OS). Our data confirmed that PD-L1 could be an important marker for prognostic stratification and for planning immune checkpoint inhibitors therapies in patients with TNBC.<\/jats:p>","DOI":"10.3390\/ijms18020459","type":"journal-article","created":{"date-parts":[[2017,2,22]],"date-time":"2017-02-22T11:40:52Z","timestamp":1487763652000},"page":"459","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":75,"title":["Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients"],"prefix":"10.3390","volume":"18","author":[{"given":"Gerardo","family":"Botti","sequence":"first","affiliation":[{"name":"Pathology Unit, Istituto Nazionale Tumori Fondazione \u201cG. Pascale\u201d, via Mariano Semmola, 80131 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9862-3668","authenticated-orcid":false,"given":"Francesca","family":"Collina","sequence":"additional","affiliation":[{"name":"Pathology Unit, Istituto Nazionale Tumori Fondazione \u201cG. Pascale\u201d, via Mariano Semmola, 80131 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giosu\u00e8","family":"Scognamiglio","sequence":"additional","affiliation":[{"name":"Pathology Unit, Istituto Nazionale Tumori Fondazione \u201cG. Pascale\u201d, via Mariano Semmola, 80131 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Rao","sequence":"additional","affiliation":[{"name":"Pathology Unit, Istituto Nazionale Tumori Fondazione \u201cG. Pascale\u201d, via Mariano Semmola, 80131 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Peluso","sequence":"additional","affiliation":[{"name":"Pathology Unit, Istituto Nazionale Tumori Fondazione \u201cG. Pascale\u201d, via Mariano Semmola, 80131 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"De Cecio","sequence":"additional","affiliation":[{"name":"Pathology Unit, Istituto Nazionale Tumori Fondazione \u201cG. Pascale\u201d, via Mariano Semmola, 80131 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1730-3900","authenticated-orcid":false,"given":"Michela","family":"Piezzo","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery and Cancer Prevention, Istituto Nazionale Tumori Fondazione \u201cG. Pascale\u201d, via Mariano Semmola, 80131 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Landi","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery and Cancer Prevention, Istituto Nazionale Tumori Fondazione \u201cG. Pascale\u201d, via Mariano Semmola, 80131 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelino","family":"De Laurentiis","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery and Cancer Prevention, Istituto Nazionale Tumori Fondazione \u201cG. Pascale\u201d, via Mariano Semmola, 80131 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Cantile","sequence":"additional","affiliation":[{"name":"Pathology Unit, Istituto Nazionale Tumori Fondazione \u201cG. Pascale\u201d, via Mariano Semmola, 80131 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Di Bonito","sequence":"additional","affiliation":[{"name":"Pathology Unit, Istituto Nazionale Tumori Fondazione \u201cG. Pascale\u201d, via Mariano Semmola, 80131 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2017,2,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1007\/s12032-013-0834-y","article-title":"Triple-negative breast cancer: Future prospects in diagnosis and management","volume":"31","author":"Elsamany","year":"2014","journal-title":"Med. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J. Clin. Investig."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"12890","DOI":"10.18632\/oncotarget.3849","article-title":"Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?","volume":"6","author":"Eckhardt","year":"2015","journal-title":"Oncotarget"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1016\/j.molimm.2008.05.014","article-title":"Interaction of human PD-L1 and B7-1","volume":"45","author":"Butte","year":"2008","journal-title":"Mol. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00428-016-1910-4","article-title":"Assessment of the PD-L1 status by immunohistochemistry: Challenges and perspectives for therapeutic strategies in lung cancer patients","volume":"468","author":"Ilie","year":"2016","journal-title":"Virchows Arch."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s10549-014-2988-5","article-title":"Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer","volume":"146","author":"Muenst","year":"2014","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1158\/2326-6066.CIR-13-0127","article-title":"PD-L1 expression in triple-negative breast cancer","volume":"2","author":"Mittendorf","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1093\/ajcp\/aqw134","article-title":"Stromal PD-L1 expression is associated with better disease-free survival in triple-negative breast cancer","volume":"146","author":"Li","year":"2016","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s12967-016-0925-6","article-title":"Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies","volume":"14","author":"Sun","year":"2016","journal-title":"Transl. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.humpath.2015.09.003","article-title":"PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas","volume":"47","author":"Thompson","year":"2016","journal-title":"Hum. Pathol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jtho.2016.11.2228","article-title":"PD-L1 immunohistochemistry assays for lung cancer: Results from Phase 1 of the \u201cblueprint PD-L1 IHC assay comparison project\u201d","volume":"12","author":"Hirsch","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"147","DOI":"10.4137\/CIN.S9983","article-title":"TNBC type: A subtyping tool for triple-negative breast cancer","volume":"11","author":"Chen","year":"2012","journal-title":"Cancer Inform."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.breast.2013.07.027","article-title":"Patients with triple negative breast cancer: Is there an optimal adjuvant treatment?","volume":"22","author":"Burstein","year":"2013","journal-title":"Breast"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.coi.2011.12.009","article-title":"Targeting the PD-1\/B7-H1 (PD-L1) pathway to activate anti-tumor immunity","volume":"24","author":"Topalian","year":"2012","journal-title":"Curr. Opin. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s10147-016-0959-z","article-title":"PD-1\/PD-L1 blockade in cancer treatment: Perspectives and issues","volume":"21","author":"Hamanishi","year":"2016","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.ctrv.2015.11.001","article-title":"Predictive biomarkers in PD-1\/PD-L1 checkpoint blockade immunotherapy","volume":"41","author":"Meng","year":"2015","journal-title":"Cancer Treat. Rev."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Soliman, H., Khalil, F., and Antonia, S. (2014). PD-L1 expression is increased in a subset of basal type breast cancer cells. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0088557"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.18632\/oncotarget.3216","article-title":"Prognostic and predictive value of PDL1 expression in breast cancer","volume":"6","author":"Sabatier","year":"2015","journal-title":"Oncotarget"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"36956","DOI":"10.1038\/srep36956","article-title":"PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients","volume":"6","author":"Kim","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1158\/1078-0432.CCR-13-2702","article-title":"In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas","volume":"20","author":"Schalper","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_21","first-page":"291546","article-title":"Obesity as a major risk factor for cancer","volume":"2013","author":"Silvestris","year":"2013","journal-title":"J. Obes."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/dom.12124","article-title":"Diabetes and cancer: Two diseases with obesity as a common risk factor","volume":"16","author":"Garg","year":"2014","journal-title":"Diabetes Obes. Metab."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1002\/jcp.25579","article-title":"Risk differences between prediabetes and diabetes according to breast cancer molecular subtypes","volume":"232","author":"Crispo","year":"2016","journal-title":"J. Cell Physiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s10552-012-0002-2","article-title":"Components of metabolic syndrome and risk of breast cancer by prognostic features in the study of osteoporotic fractures cohort","volume":"23","author":"Reeves","year":"2012","journal-title":"Cancer Cause Control."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13058-015-0598-8","article-title":"Metformin in breast cancer\u2014An evolving mystery","volume":"17","author":"Camacho","year":"2015","journal-title":"Breast Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1530\/ERC-15-0507","article-title":"Hyperglycaemia-induced chemoresistance in breast cancer cells: Role of the estrogen receptor","volume":"23","author":"Zeng","year":"2016","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_27","first-page":"1175","article-title":"Tissue micro arrays for immunohistochemical detection of inflammatory infiltrates in renal cell carcinoma","volume":"7","author":"Scognamiglio","year":"2014","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Scognamiglio, G., de Chiara, A., di Bonito, M., Tatangelo, F., Losito, N.S., Anniciello, A., de Cecio, R., D\u2019Alterio, C., Scala, S., and Cantile, M. (2016). Variability in immunohistochemical detection of programmed death ligand 1 (PD-L1) in cancer tissue types. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17050790"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/modpathol.2008.72","article-title":"Tumor infiltrating lymphocytes differ in invasive micropapillary carcinoma and medullary carcinoma of breast","volume":"21","author":"Guo","year":"2008","journal-title":"Mod. Pathol."},{"key":"ref_30","first-page":"3530","article-title":"Downregulation of androgen receptor is strongly associated with diabetes in triple negative breast cancer patients","volume":"8","author":"Collina","year":"2016","journal-title":"Am. J. Transl. Res."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/18\/2\/459\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T18:28:45Z","timestamp":1760207325000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/18\/2\/459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,21]]},"references-count":30,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,2]]}},"alternative-id":["ijms18020459"],"URL":"https:\/\/doi.org\/10.3390\/ijms18020459","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,21]]}}}